Isha Narang
Research Subjects
Research Interests
Isha Narang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
B. Chohan
Department ofPathology University Hospitals of Derby and Burton NHS Foundation Trust Derby UK
2 shared publicationsJulie Smith
Departments of Paediatrics, University Hospitals of Derby and Burton NHS Foundation , Derby , UK
2 shared publicationsR. Nambi
Department ofDepartment of DermatologyUniversity Hospitals of Derby and Burton DerbyUK
2 shared publicationsA. Ferguson
Department ofDepartment of DermatologyUniversity Hospitals of Derby and Burton DerbyUK
1 shared publicationA. P. Panthagani
Department ofDepartment of DermatologyUniversity Hospitals of Derby and Burton DerbyUK
1 shared publicationC.G. Bertram
Royal Infirmary of Edinburgh Edinburgh UK
1 shared publication
Latest Publications
- Open Access
- 16 November 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 48 (4) , 382-383
The National Institute for Health and Care Excellence recommends glucose monitoring devices for all patients with Type 1 diabetes: anticipating further increase in cutaneous reactions to these devices
- 16 November 2022
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 48 (4) , 382-383
Open AccessThe National Institute for Health and Care Excellence recommends glucose monitoring devices for all patients with Type 1 diabetes: anticipating further increase in cutaneous reactions to these devices
- Open Access
- 30 September 2021
- Published by BMJ
- Vol. 106 (Suppl 1) , A80
677 Cutaneous reactions to glucose sensors: a sticky problem
Background Glucose sensors (GS) are increasingly used in children and young people (CYP) with Type 1 diabetes. Improved outcome has been associated with their use. However since their introduction, cutaneous reactions have been reported. Both irritant and allergic contact dermatitis (ACD) can be caused by constituents of these devices. Manufacturers are not under any legal obligation to disclose the constituents of the sensor. This makes identification of the allergen by patch test challenging and selection of an alternative device difficult. Since the introduction of these devices in our paediatric diabetes service, we have seen an increasing number of these reactions. All cases are reported to Medicines and Health Regulatory Agency (MHRA) and referred to the Paediatric dermatologist. The relevant manufacturer is contacted to seek details of the constituents. This information has not been forthcoming. Objectives The purpose of this study was to review our local experience of contract dermatitis and determine if our experience was reflected nationally and whether all teams were reporting cases to the MHRA and referring to dermatologists for investigation. Methods We reviewed all cases in our service to determine incidence with each device and the results of patch testing if done. In June 2020, we carried out a survey to paediatric diabetes and dermatology teams in England to determine the number of cases of contact dermatitis seen, the devices involved and whether MHRA reporting and referral to dermatology for investigation was routine practice. Results By 2019, in our service, 12.5% of Dexcom G5 users had experienced a skin reaction, 0% of Dexcom G6, 30% of Medtronic and 3.5% of Free Style Libre (FSL). Since 2019, the FSL formulation has been IBOA free and we have seen no further reactions. Dexcom G6 had a new formulation in 2019 which is IBOA free. Since 2020, we have noticed reactions in 6/55 (10.9%) of our patients. Dexcom has not disclosed the potential allergens in this new formulation, hindering further investigation. From the national survey, we received responses from 61 out of 173 teams giving data on 10487 CYP. GS were used in 61%(6419). 5% (320) had developed a skin reaction likely to be contact dermatitis. The GS implicated were Dexcom G6 (5% of its users), G5 (7.4%), Medtronic Enlite Sensor(15%), Medtronic Guardian Sensor 3(8.8%),and Freestyle libre (3.7%). Only 5 teams had reported the reaction to MHRA via the Yellow Alert scheme and only 6 teams had referred to dermatology for further investigation and management. Conclusions Our survey confirmed the problem is widespread, with under reporting of these cases in England to the MHRA. Dermatology referral is often not sought. It is essential that all cases are reported to raise awareness of this problem which is impacting the care of children with Type 1 diabetes. Working closely with dermatology team can help to find ways to manage these patients. Manufacturers must be more transparent in their labelling and modify their formulation if an increased rate of reaction occurs.
- 30 September 2021
- Published by BMJ
- Vol. 106 (Suppl 1) , A80
Open Access677 Cutaneous reactions to glucose sensors: a sticky problem
Background Glucose sensors (GS) are increasingly used in children and young people (CYP) with Type 1 diabetes. Improved outcome has been associated with their use. However since their introduction, cutaneous reactions have been reported. Both irritant and allergic contact dermatitis (ACD) can be caused by constituents of these devices. Manufacturers are not under any legal obligation to disclose the constituents of the sensor. This makes identification of the allergen by patch test challenging and selection of an alternative device difficult. Since the introduction of these devices in our paediatric diabetes service, we have seen an increasing number of these reactions. All cases are reported to Medicines and Health Regulatory Agency (MHRA) and referred to the Paediatric dermatologist. The relevant manufacturer is contacted to seek details of the constituents. This information has not been forthcoming. Objectives The purpose of this study was to review our local experience of contract dermatitis and determine if our experience was reflected nationally and whether all teams were reporting cases to the MHRA and referring to dermatologists for investigation. Methods We reviewed all cases in our service to determine incidence with each device and the results of patch testing if done. In June 2020, we carried out a survey to paediatric diabetes and dermatology teams in England to determine the number of cases of contact dermatitis seen, the devices involved and whether MHRA reporting and referral to dermatology for investigation was routine practice. Results By 2019, in our service, 12.5% of Dexcom G5 users had experienced a skin reaction, 0% of Dexcom G6, 30% of Medtronic and 3.5% of Free Style Libre (FSL). Since 2019, the FSL formulation has been IBOA free and we have seen no further reactions. Dexcom G6 had a new formulation in 2019 which is IBOA free. Since 2020, we have noticed reactions in 6/55 (10.9%) of our patients. Dexcom has not disclosed the potential allergens in this new formulation, hindering further investigation. From the national survey, we received responses from 61 out of 173 teams giving data on 10487 CYP. GS were used in 61%(6419). 5% (320) had developed a skin reaction likely to be contact dermatitis. The GS implicated were Dexcom G6 (5% of its users), G5 (7.4%), Medtronic Enlite Sensor(15%), Medtronic Guardian Sensor 3(8.8%),and Freestyle libre (3.7%). Only 5 teams had reported the reaction to MHRA via the Yellow Alert scheme and only 6 teams had referred to dermatology for further investigation and management. Conclusions Our survey confirmed the problem is widespread, with under reporting of these cases in England to the MHRA. Dermatology referral is often not sought. It is essential that all cases are reported to raise awareness of this problem which is impacting the care of children with Type 1 diabetes. Working closely with dermatology team can help to find ways to manage these patients. Manufacturers must be more transparent in their labelling and modify their formulation if an increased rate of reaction occurs.
- 29 June 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (8) , 1653-1655
Degos disease with renal cell carcinoma
- 29 June 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (8) , 1653-1655
Degos disease with renal cell carcinoma
- Open Access
- 1 March 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (3) , 575-577
Occupational dermatoses during the COVID‐19 pandemic: a multicentre audit in the UK and Ireland
- 1 March 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (3) , 575-577
Open AccessOccupational dermatoses during the COVID‐19 pandemic: a multicentre audit in the UK and Ireland
- Open Access
- 28 January 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (5) , 927-929
COVID‐19‐induced toxic epidermal necrolysis
Click on the article title to read more.
- 28 January 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (5) , 927-929
Open AccessCOVID‐19‐induced toxic epidermal necrolysis
Click on the article title to read more.
- 1 December 2020
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 45 (8) , 1100-1102
x A unique 'hand in bucket' sign in a case of acquired unilateral aquagenic syringeal acrokeratoderma
- 1 December 2020
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 45 (8) , 1100-1102
x A unique 'hand in bucket' sign in a case of acquired unilateral aquagenic syringeal acrokeratoderma
- Open Access
- 24 January 2019
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 5 (2) , 92-95
An array of unusual clinical features in a woman with amlodipine-induced linear immunoglobulin A disease
Linear immunoglobulin A disease (LAD) is a rare, autoimmune, vesicular-bullous disease that is either idiopathic or drug-induced, most commonly by vancomycin and in rare instances by amlodipine. In drug-induced LAD, certain uncommon and atypical clinical features can occur. In our patient, a 49-year-old woman with amlodipine-induced LAD, atypical features such as koebnerization and palmo-plantar involvement occurred. She presented with tense, clear fluid-filled vesicles, bullae, and erosions all over her body, especially on the palms and soles, with some lesions showing a string-of-pearls appearance. The lesions were preceded by pruritus, and the patient had changed her anti-hypertensive medication from telmisartan to telmisartan-amlodipine for previous 10 days. Skin biopsy and direct immunofluorescence testing confirmed LAD. During the hospital stay, along with new crops of lesions, a few vesicles were present along the lines where she had scratched and the band of tight elastic sleeves of the sterile gown she wore, which is suggestive of koebnerization. Knowing the atypical manifestations of drug-induced LAD may aid clinicians in determining an early diagnosis, and LAD should be an important consideration in the differential diagnosis of vesiculobullous disease with palmar-plantar involvement. Amlodipine is a commonly used anti-hypertensive drug, so knowledge of its potential to cause this disease is important. Furthermore, knowing the potential for koebnerization, avoidance of trauma and the gentle handling of these patients can lead to early recovery from this self-limiting disease.
- 24 January 2019
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 5 (2) , 92-95
Open AccessAn array of unusual clinical features in a woman with amlodipine-induced linear immunoglobulin A disease
Linear immunoglobulin A disease (LAD) is a rare, autoimmune, vesicular-bullous disease that is either idiopathic or drug-induced, most commonly by vancomycin and in rare instances by amlodipine. In drug-induced LAD, certain uncommon and atypical clinical features can occur. In our patient, a 49-year-old woman with amlodipine-induced LAD, atypical features such as koebnerization and palmo-plantar involvement occurred. She presented with tense, clear fluid-filled vesicles, bullae, and erosions all over her body, especially on the palms and soles, with some lesions showing a string-of-pearls appearance. The lesions were preceded by pruritus, and the patient had changed her anti-hypertensive medication from telmisartan to telmisartan-amlodipine for previous 10 days. Skin biopsy and direct immunofluorescence testing confirmed LAD. During the hospital stay, along with new crops of lesions, a few vesicles were present along the lines where she had scratched and the band of tight elastic sleeves of the sterile gown she wore, which is suggestive of koebnerization. Knowing the atypical manifestations of drug-induced LAD may aid clinicians in determining an early diagnosis, and LAD should be an important consideration in the differential diagnosis of vesiculobullous disease with palmar-plantar involvement. Amlodipine is a commonly used anti-hypertensive drug, so knowledge of its potential to cause this disease is important. Furthermore, knowing the potential for koebnerization, avoidance of trauma and the gentle handling of these patients can lead to early recovery from this self-limiting disease.